Elucidating the Molecular Basis of Sorafenib Resistance in HCC: Current Findings and Future Directions

Hepatocellular carcinoma (HCC) is the second leading cause of cancer-related mortality worldwide. Sorafenib is the first multi-tyrosine kinase inhibitor approved for HCC and it has represented the standard of care for advanced HCC for almost 10 years, offering a survival benefit when compared to pla...

Full description

Saved in:
Bibliographic Details
Published in:J Hepatocell Carcinoma
Main Authors: Fornari, Francesca, Giovannini, Catia, Piscaglia, Fabio, Gramantieri, Laura
Format: Artigo
Language:Inglês
Published: Dove 2021
Subjects:
Review
Online Access:https://ncbi.nlm.nih.gov/pmc/articles/PMC8260177/
https://ncbi.nlm.nih.gov/pubmed/34239844
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.2147/JHC.S285726
Tags: Add Tag
No Tags, Be the first to tag this record!

Similar Items